Effects of Medications in Patients With Hypogonadism

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of the present study was to demonstrate the influences of three different treatment strategies on biochemical parameters and testicular volume (TV) in patients with idiopathic hypogonadotropic hypogonadism (IHH).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gulhane School of Medicine
• Treatments: Chorionic Gonadotropin; Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria: hypogonadotropic hypogonadism

• decreased serum testosterone concentration below the normal range (serum T < 300ng/dL),

• FSH and LH levels within or below the normal range,

• absence of a pituitary or hypothalamic mass lesions on MRI, presence of gonadotropin response to repetitive doses of GnRH,

• normal smell test and normal karyotypes

Exclusion Criteria:

• previous androgen treatment,

• history of smoking,

• presence of bilateral anorchia,

• intellectual deficiency,

• diabetes mellitus,

• arterial hypertension or dyslipoproteinemia,

• medication of any kind and drug abuse. Because of possible confounding effects, patients with other hormone deficiencies were excluded.

Participants with iron, vitamin B12 or folate deficiency were also excluded.